Two amyloid-targeting Alzheimer’s disease therapies had Phase III trials read out in the last month, with divergent results that reflect the risk-strewn landscape for sponsors trying to study the neurodegenerative disease: Roche Holding AG pulled the plug on its early AD program for gantenerumab for lack of efficacy in the GRADUATE program, while Biogen, Inc. and Eisai Co., Ltd. won plaudits for lecanemab’s showing in the CLARITY AD trial as best evidence yet of a disease-modifying effect.
The high level of unmet need in Alzheimer’s disease contributed to the FDA's decision to award accelerated approval to Biogen's...







